Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance to surging royalty revenue and a wave of new collaboration agreements. CEO Helen Torley highlighted that the ENHANZE platform, now underpinning revenue from six different drugs, enabled a record 50% year-over-year royalty growth. The quarter also benefited from sizable milestone payments tied to newly signed licensing deals, with Torley emphasizing, “The ENHANZE value proposition is attracting new partners and additional products from our current partners at a cracking pace.”
Is now the time to buy HALO? Find out in our full research report (it’s free for active Edge members).
Halozyme Therapeutics (HALO) Q2 CY2026 Highlights:
- Revenue: $481 million vs analyst estimates of $404.3 million (47.7% year-on-year growth, 19% beat)
- Adjusted EPS: $2.28 vs analyst estimates of $1.82 (25.5% beat)
- Adjusted EBITDA: $328.8 million vs analyst estimates of $267.2 million (68.4% margin, 23.1% beat)
- The company lifted its revenue guidance for the full year to $1.87 billion at the midpoint from $1.76 billion, a 6.4% increase
- Management raised its full-year Adjusted EPS guidance to $8.83 at the midpoint, a 10.3% increase
- EBITDA guidance for the full year is $1.25 billion at the midpoint, above analyst estimates of $1.16 billion
- Operating Margin: 59.8%, down from 62.2% in the same quarter last year
- Market Capitalization: $11.55 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call
- Natasha (Morgan Stanley) asked about the drivers behind the implied acceleration in royalty revenue for the second half of the year. CFO Darren Snellgrove explained that new product launches, such as Rybrevant subcutaneous, are expected to drive sequential growth, though not at the same steep pace as between Q1 and Q2.
- Jaya (Evercore ISI) inquired about the future of target exclusivity as patents expire and whether this opens new licensing opportunities. CEO Helen Torley clarified that deal structures are increasingly flexible, with a mix of exclusive and non-exclusive agreements tailored to partner needs.
- Brendan Smith (TD Cowen) pressed for more detail on the timing and scale of Hypercon pipeline launches and whether royalty projections include future partnerships. Torley responded that five to seven product launches by the mid-2030s underpin the $1 billion royalty target, with current and potential future deals contributing.
- Amit (H.C. Wainwright) asked how the mix of new versus follow-on partner nominations and the entry into ADCs and nucleic acids will shape future deal cadence. Torley emphasized that both new deals and nominations from existing partners are expected to drive pipeline growth.
- David Risinger (Leerink Partners) requested updates on Merck litigation, Alteogen competition, and M&A strategy. Torley outlined ongoing legal actions and stressed Halozyme’s competitive advantages, while Snellgrove reiterated disciplined but flexible capital allocation for future M&A.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will focus on (1) the pace of new ENHANZE and Hypercon partnership agreements and whether these expand further into ADCs and nucleic acids, (2) the ramp-up of royalty revenue contributions from newly launched subcutaneous products, and (3) progress toward clinical milestones, especially the target of 13 ENHANZE development programs by year-end. We will also monitor developments in patent litigation and any updates on manufacturing investments for Hypercon.
Halozyme Therapeutics currently trades at $102.10, up from $85.76 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
